Strides Pharma Science
Market cap ₹8,831 Cr
- P/E
- 14.32
- Day range
- ₹956.70 – ₹990.50
- 52-week range
- ₹768.65 – ₹1,260.90
- Volume
- 2.81 L
- Open
- ₹983.00
- Prev close
- ₹982.10
Latest results · Q2 FY27(consolidated)Revenue ₹1,430 Cr+17.1%Profit ₹134 Cr+2.0%Margin 9.4%YoY vs the same quarter last year
1 red flag to read up on
- high
High promoter pledge
33.79% of promoter shares pledged · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
STAR in NSE indices and F&O
Research profile
Composite 64 / 100Factor percentiles
Derived metrics
- Earn. yield
- 7.0%
- Graham no.
- ₹713.73
- vs Graham
- -25.5%
- ROE ÷ P/B
- 7.7%
- 12-1 mom.
- +12.5%
- Return / vol
- 0.08
- Magic Formula
- #104
- Piotroski
- 5/6
- FCF yield
- 3.1%
Appears in 10 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Strides Pharma ScienceSTAR | ₹8,831 Cr | 14.32 | 2.65 | 20.3% | 18.0% | 18.0% | 0.56 | +17.1% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Key metrics
- P/E (TTM)
- 15.7
- Price / Book
- 2.58
- ROE (FY26)
- 20.3%
- ROCE (latest year)
- 18%
- Dividend yield
- 0.51%
Moving averages (NSE)
- 20-day
- ₹1,023.21
- Price below
- 50-day
- ₹1,094.01
- Price below
- 200-day
- ₹1,025.99
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- FII
- Public
- DII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 | 1,430 |
| Expenses | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 | 1,179 |
| Operating Profit | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 | 251 |
| OPM % | 13% | 16% | 18% | 16% | 18% | 18% | 19% | 19% | 20% | 18% | 18% | 18% |
| Other Income | 60 | -27 | 3,299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 | 3 |
| Interest | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 | 47 |
| Depreciation | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 | 57 |
| Profit before tax | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 | 150 |
| Tax % | 23% | 55% | 1% | 16% | 21% | 20% | 13% | 14% | 15% | 13% | 17% | 11% |
| Net Profit | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 | 134 |
| EPS in Rs | ₹5.40 | ₹1.98 | ₹364.69 | ₹7.81 | ₹9.54 | ₹8.91 | ₹10.80 | ₹13.84 | ₹21.93 | ₹13.77 | ₹17.02 | ₹14.20 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-25 days since Mar 2021
-24 days since Mar 2021
-79 days since Mar 2021
+29 days since Mar 2021
+60 days since Mar 2021
Strengths, risks & growth
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. [1] The company's pharmaceutical products are sold in over 100 countries. [2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure. [3]
Strengths
- Company has delivered good profit growth of 20.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%
Risks
- Stock is trading at 2.65 times its book value
- The company has delivered a poor sales growth of 7.94% over past five years.
- Promoter holding is low: 29.0%
- Promoters have pledged 33.8% of their holding.
Compounded Sales Growth
- 10 Years
- +5%
- 5 Years
- +8%
- 3 Years
- +10%
- TTM
- +11%
Compounded Profit Growth
- 10 Years
- +16%
- 5 Years
- +20%
- 3 Years
- +71%
- TTM
- +33%
Stock Price CAGR
- 10 Years
- +7%
- 5 Years
- +33%
- 3 Years
- +63%
- 1 Year
- +4%
Return on Equity
- 10 Years
- +22%
- 5 Years
- +31%
- 3 Years
- +57%
- Last Year
- +20%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 27.86% | 27.91% | 27.91% | 29.00% | +1.09 pp |
| FII | 29.52% | 28.68% | 28.40% | 27.98% | -0.42 pp |
| DII | 13.02% | 14.44% | 15.42% | 15.51% | +0.09 pp |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.00 pp |
| Public | 29.59% | 28.96% | 28.28% | 27.52% | -0.76 pp |
Filed with NSE for Sept 2026: promoters 29.00%, public 71.00%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 10.31% (+1.58 pp)- Promoters29.0%
- Foreign institutions28.0%
- Mutual funds10.3%
- Insurance3.5%
- Other domestic institutions1.6%
- Retail12.7%
- Others14.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Quant Small Cap Fund | 4.64% | 1.24% | +0.15 pp |
| Bandhan Small Cap Fund | 3.79% | 0.97% | +0.38 pp |
| Quant Multi Cap Fund | 1.75% | 2.11% | +0.22 pp |
| Axis Small Cap Fund | 0.87% | 0.27% | +0.02 pp |
| Quant Healthcare Fund | 0.40% | 8.79% | +6.15 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 37.1%
- Downside volatility
- 32.8%
- Worst 5% of days
- 3.9%
- Average of that tail
- 4.6%
- Max drawdown (1Y)
- 22.4%
- Below its peak
- 22.4%
Against the market
- Beta vs Nifty 50
- 0.50
- Correlation
- 0.18
- Relative strength (3M)
- -6.8%
- ATR (14)
- 4.0%
Return
- Return 1M
- -8.3%
- Return 3M
- -2.9%
- Return 6M
- -16.8%
- Return 1Y
- +3.1%
- vs 200-day average
- -6.6%
Momentum
- RSI (14)
- 31.0
- MACD histogram
- -4.10
- Stochastic %K
- 0.9
- ADX (14)
- 31.6
- +DI / −DI
- 12.1 / 29.4
- Money flow index
- 20.9
Participation
- Delivery (20d avg)
- 49.6%
- vs its 60-day baseline
- +1.6 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.8%
- 52-week position
- 37 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹285 Cr
- FCF yield
- 3.1%
- Cash conversion
- 1.22
- Accruals ratio
- -0.018
- Net debt
- ₹1,768 Cr
- Net debt / equity
- 0.52
- EV / sales
- 2.08
- Capex intensity
- 8.6%
- Revenue CAGR
- 13.0%
- Profit CAGR
- 34.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹5.00
Dividend - Rs 5 Per Share
31 Jul 2026ex-date - dividend₹4.00
Dividend - Rs 4 Per Share
22 Jul 2025ex-date - otherNot available — not reported in this filing
Demerger
6 Dec 2024ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
9 Sept 2024ex-date - dividend₹1.50
Dividend - Rs 1.50 Per Share
4 Aug 2023ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
5 Aug 2021ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
24 Jul 2020ex-date - dividend₹12.00
Interim Dividend - Rs 12 Per Share
22 Aug 2019ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
19 Jul 2019ex-date - dividend₹2.00
Annual General Meeting/Dividend Rs 2 Per Share
12 Sept 2018ex-date - otherNot available — not reported in this filing
Scheme Of Arrangement
6 Apr 2018ex-date - dividend₹4.50
Annual General Meeting/Dividend - Rs 4.50 Per Share
7 Sept 2017ex-date - dividend₹4.00
Annual General Meeting/ Dividend - Rs 4/- Per Share
21 Jul 2016ex-date - dividend₹3.00
Annual General Meeting/ Dividend - Rs 3/- Per Share
22 Jul 2015ex-date - dividend₹105.00
Special Dividend Rs.105/- Per Share
16 Oct 2014ex-date - dividend₹5.00
Annual General Meeting / Dividend - Rs 5/- Per Share
1 Sept 2014ex-date - dividend₹500.00
Special Dividend - Rs 500/- Per Share
19 Dec 2013ex-date - dividend₹2.00
Annual General Meeting And Dividend Rs.2/- Per Share
30 May 2013ex-date - dividend₹2.00
Annual General Meeting And Dividend Rs.2/- Per Share
14 May 2012ex-date - dividend₹1.50
Annual General Meeting And Dividend Rs.1.50 Per Share
18 May 2011ex-date
Company announcements
Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026
Closure of Trading Window for the quarter ended September 30, 2026
Strides' Sustainability Report for FY26
Completion of USFDA Inspection at the Company's Formulation Facility at Alathur
Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru
Voting results along with Scrutinizers report for 35th AGM.
Proceedings of 35th Annual General Meeting of the Company
Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Newspaper advertisement - Unaudited Financial Results for the quarter ended June 30, 2026
Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY27
Earnings Presentation for the quarter ended June 30, 2026
Strides Delivers Steady Performance with Q1FY27; Revenue at Rs. 12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY
Outcome of Board Meeting of the Company held on July 31, 2026
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited financial ....
Filed with BSE (scrip 532531); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
- Nov 2025TranscriptSlides
- Aug 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 12 Oct from care
- Rating update · 8 Jul from care
- Rating update · 26 Dec 2025 from care
- Rating update · 2 Jul 2025 from care
- Rating update · 31 Mar 2025 from care
- Rating update · 13 Mar 2025 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Strides Pharma Science: common questions
Answered from the figures on this page.